The rapid evolution of oligonucleotide therapeutics has paved the way for groundbreaking treatments across a spectrum of diseases. With over 20 FDA- and EMA-approved drugs at the time of writing, and many more in clinical trials, this field is transforming modern medicine. However, for these therapies to be both effective and safe, precise oligonucleotide structural characterization is essential.
Oligonucleotide drugs offer a unique mechanism of action compared to traditional small molecules and biologics. By targeting mRNA, these therapies can either down-regulate protein expression or modulate mRNA splicing to correct genetic mutations. With modified ribose sugars, phosphorothioate (PS) backbones, and phosphorodiamidate morpholino nucleotides, these molecules are designed for increased stability and specificity.
BioPharmaSpec’s latest White Paper focuses on the characterization of Inotersen and Unmodified Inotersen as models, exploring mass spectrometry-based techniques to confirm structural integrity, sequence identity, and impurity profiling—critical elements in the development of these promising drugs.
Inotersen, a single-stranded antisense oligonucleotide (ASO), degrades target mRNA via RNAse H activation. This mechanism is crucial for treating hereditary transthyretin amyloidosis (hATTR), a rare but severe genetic disorder. Understanding the chemical structure of Inotersen and its unmodified version is vital to ensuring its safety and efficacy.
While Inotersen is a chemically modified ASO with 2’-MOE modifications and a phosphorothioate backbone, Unmodified Inotersen lacks these enhancements. It has been shown that as a result of the differences in their structural properties, with Inotersen demonstrating superior stability and resistance to enzymatic degradation. This highlights the importance of modifications in optimizing therapeutic performance.
Developing oligonucleotide drugs requires precise analytical methodologies. An additional BioPharmaSpec Technical Bulletin, “Effective Structural Characterization Strategies for Oligonucleotides” outlines the following essential oligonucleotide structural characterization techniques:
The field of oligonucleotide therapeutics continues to expand, and comprehensive characterization strategies remain essential. BioPharmaSpec’s oligonucleotide resources, including the Technical Bulletin and White Paper below, provide invaluable insights into these methodologies, serving as a guide for researchers and pharmaceutical developers.
For those seeking a deeper understanding of oligonucleotide structural characterization and its role in drug development, we highly recommend reading these guides. Dive into the world of advanced analytical techniques with BioPharmaSpec and discover how they can help shape the future of precision medicine.
Design effective structural characterization studies for oligonucleotide therapeutics.
Example data from the analysis of unmodified Inotersen and Inotersen.
